News

Public · Published

JP Morgan maintains Halozyme Therapeutics at Neutral, raises price target to $79 from $78

JP Morgan kept its Neutral rating on Halozyme Therapeutics and raised its price target to $79 from $78, a 1.3% increase. That target implies a 38.7% downside from the November 2 close of $128.95.

Published:

Updated:

What happened

JP Morgan kept its Neutral rating on Halozyme Therapeutics and raised its price target to $79 from $78, a 1.3% increase. That target implies a 38.7% downside from the November 2 close of $128.95.

Confirmed

Global impact / market context

The new target sits far below the recent share price, so JP Morgan sees limited upside even after a small increase. A Neutral rating tells clients not to expect a big move, which can temper buying interest from investors who follow analyst ratings.

Analyst inference

Recent analyst targets on Halozyme range from $78 to $130, showing wide disagreement about the company's worth. Two other firms rate it Buy with $130 targets, so JP Morgan's Neutral view is the most cautious among the three recent notes.

Analyst inference

What to watch

  1. The November 2 close of $128.95 was far above JP Morgan's $79 target, so watch whether the share price moves closer to that target over time. Confirmed
  2. Watch whether other analysts change their $130 targets or Buy ratings, since a shift by either firm would change the balance of opinion. Proposed
  3. Watch Halozyme's next financial results, because stronger revenue or profit could push targets higher, while weaker results could support JP Morgan's cautious stance. Analyst inference

Evidence

  • Original source link unavailable